Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Portfolio Pulse from Vandana Singh
Goldman Sachs has initiated coverage on Regenxbio Inc (NASDAQ:RGNX) with a Buy rating and a price target of $38, citing the potential of its gene therapy pipeline. The company's pipeline includes treatments for ophthalmology, Duchenne muscular dystrophy, and Hunter syndrome. Goldman Sachs anticipates that upcoming data releases and filings will boost Regenxbio's share performance.
June 07, 2024 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs seeks clarification on how Regenxbio's approach differs from competing programs like 4D Molecular Therapeutics Inc.
Goldman Sachs' interest in understanding the differences between Regenxbio's and 4D Molecular Therapeutics' approaches indicates potential competition but does not directly impact FDMT's stock price.
CONFIDENCE 60
IMPORTANCE 50
RELEVANCE 20
NEUTRAL IMPACT
Regenxbio's RGX-314 will face competition from Regeneron Pharmaceutical's Eylea, which has set high standards of efficacy and safety in the market.
While Regenxbio's RGX-314 is a potential competitor, Regeneron's Eylea has already set high standards in the market, which may limit RGX-314's market penetration.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
AbbVie Inc's significant presence in ophthalmology could support Regenxbio's market penetration for RGX-314.
AbbVie's established presence in ophthalmology could provide a supportive environment for Regenxbio's RGX-314, potentially aiding its market penetration.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 30
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Regenxbio Inc with a Buy rating and a price target of $38, citing the potential of its gene therapy pipeline. Upcoming data releases and filings are expected to boost share performance.
Goldman Sachs' Buy rating and high price target indicate strong confidence in Regenxbio's gene therapy pipeline. Upcoming data releases and filings are expected to positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100